title: Arg and DAP3 expression was correlated with human thymoma stage.
abstract: Thymoma is one of the most common solid tumors in the mediastinum. As there is no typical cell line for human thymoma, the development and use of molecular-based therapy for thymoma will require detailed molecular genetic analysis of patients' tissues. The recent reports showed that the gain of chromosome 1q regions was frequent in thymoma. We investigated the use of oligonucleotide arrays to monitor in vivo gene expression levels at chromosome 1q regions in the early- (stage I or II) and late-stage (stage IVa) thymoma tissues from patients. These in vivo gene expression profiles were verified by real-time quantitative reverse transcription polymerase chain reaction (RT-PCR) using LightCycler for 36 thymoma patients. Using both the methods, candidate genes were come up. These are Arg tyrosine kinase and death-associated protein 3 (DAP3), which are known as ionizing radiation resistance conferring proteins. The Arg/GAPDH mRNA level in stage IV thymoma (90.716 +/- 177.851) was significantly higher than in stage I thymoma (10.335 +/- 25.744, P = 0.0465). The DAP3/GAPDH mRNA level in stage IV thymoma (17.424 +/- 20.649) was significantly higher than in stage I thymoma (5.184 +/- 3.878, P = 0.0305). DAP3 expression was also correlated with the WHO classification. The combined use of oligonucleotide microarray and real-time RT-PCR analyses provided a candidate molecular marker surrounding the development and progression of thymoma correlated with chromosome 1q.
authors.affiliation: Department of Surgery II, Nagoya City University Medical School, Nagoya, Japan. hisasaki@med.nagoya-cu.ac.jp
authors.forename: Hidefumi
authors.initials: H
authors.lastname: Sasaki
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Ide
authors.forename: Haruhiro
authors.initials: H
authors.lastname: Yukiue
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Ichiro
authors.initials: I
authors.lastname: Fukai
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Yamakawa
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Fujii
mesh_terms: D051017:Apoptosis Regulatory Proteins; D018076:DNA, Complementary; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis; D009367:Neoplasm Staging; D020411:Oligonucleotide Array Sequence Analysis; D011505:Protein-Tyrosine Kinases / Q000235:genetics* / Q000378:metabolism; D011506:Proteins / Q000235:genetics* / Q000378:metabolism; D012333:RNA, Messenger / Q000032:analysis; D012334:RNA, Neoplasm / Q000235:genetics / Q000378:metabolism; D016601:RNA-Binding Proteins; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012269:Ribosomal Proteins; D013945:Thymoma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D013953:Thymus Neoplasms
chemical_list: D051017:Apoptosis Regulatory Proteins; C097041:DAP3 protein, human; D018076:DNA, Complementary; D011506:Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D016601:RNA-Binding Proteins; D012269:Ribosomal Proteins; C426236:ARG tyrosine kinase; D011505:Protein-Tyrosine Kinases